Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)

Q: What does CUSIP 004890109 represent in this 13F holders report?

CUSIP 004890109 is the security identifier for ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q1 2025?

60 institutional investors reported ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q1 2025. Use the holders table for investor-level position and value details.

CUSIP: 004890109

Q1 2025 13F Holders as of 31 Mar 2025

Security type / class: Equity / Common Stock, par value $0.001 per share
Total 13F shares: 22,517,048
Total 13F value: $45,710,668
Share change: -732,698
SEC-reported price per share: $2.03
Number of holders: 60
Value change: -$2,113,900
Number of buys: 21
Number of sells: 27
Shares outstanding: 43,193,792

Security key

004890109

Report period

Q1 2025

Institutions

Top holders

ACRV full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2025 Acrivon Therapeutics, Inc. SEC filings Acrivon Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 004890109

Newer quarter: Q3 2025

Recent filing periods:

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Chione Ltd

Disclosed value leader

RA CAPITAL MANAGEMENT, L.P.

Comparable rows

0/15

Latest evidence

31 Dec 2024

3/4/5 13F Highest disclosed value: $50,209,858 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $50.21M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.

Disclosed position value Top 5

Chione Ltd $16.74M

Wellington Biomedical Innovation ... $3.86M

RA CAPITAL MANAGEMENT, L.P. $50.21M

PERCEPTIVE ADVISORS LLC $32.27M

Sands Capital Alternatives, LLC $12.78M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Chione Ltd	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$16,741,549 3,848,632 shares	—	26 Jun 2023
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$3,863,366 888,130 shares	—	17 Nov 2022
RA CAPITAL MANAGEMENT, L.P.	13F Company 13F	— denominator unverified	$50,209,858 8,340,508 shares	—	31 Dec 2024
PERCEPTIVE ADVISORS LLC	13F Company 13F	— denominator unverified	$32,272,365 5,360,858 shares	—	31 Dec 2024
Sands Capital Alternatives, LLC	13F Company 13F	— denominator unverified	$12,778,082 2,122,605 shares	—	31 Dec 2024
CITADEL ADVISORS LLC	13F Company 13F	— denominator unverified	$12,760,269 2,119,646 shares	—	31 Dec 2024

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

22,517,048

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2025 vs Q2 2026 Across Filers

Q2 2026 holders

Q1 2025 holders

Holder diff

Investor	Q2 2026 Shares	Q1 2025 Shares	Share Diff	Share Chg %	Q2 2026 value	Q1 2025 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend